University of Michigan Rogel Cancer Center: Carcinoma, Non-Small-Cell Lung trials

The registry lists 12 Carcinoma, Non-Small-Cell Lung studies with University of Michigan Rogel Cancer Center as lead sponsor. 1 are open to participants now and 5 have results posted.

Early Phase 1 2Phase 1 4Phase 2 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Gilteritinib for the Treatment of ALK NSCLCRecruitingNCT06225427Phase 1
• Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03559049Phase 1/2Results posted
• Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung CancerTerminatedNCT03228186Phase 2Results posted
• A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung CancerCompletedNCT02492867Not applicableResults posted
• Using FDG-PET During Radiation Therapy in Non-Small Cell Lung CancerCompletedNCT01190527Not applicableResults posted
• Phase I/II Calcitriol in Lung CancerTerminatedNCT00794547Phase 1/2Results posted
• A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLCCompletedNCT02463994Early Phase 1
• Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsWithdrawnNCT02277457Early Phase 1
• A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung CancerTerminatedNCT01409681
• Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung CancerCompletedNCT00603057
• Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.TerminatedNCT00565227Phase 1
• Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression ProfilingTerminatedNCT00161278Phase 2